Dostarlimab

Dostarlimab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	PDCD1
Clinical data
Trade names	Jemperli
Other names	TSR-042, WBP-285, dostarlimab-gxly
AHFS/Drugs.com	Monograph
MedlinePlus	a621030
License data	US DailyMed: Dostarlimab;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
Drug class	Antineoplastic
ATC code	L01FF07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	2022215-59-2;
PubChem SID	384585344;
DrugBank	DB15627;
UNII	P0GVQ9A4S5;
KEGG	D11366;
Chemical and physical data
Formula	C6420H9832N1690O2014S44
Molar mass	144325.73 g·mol−1

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.

The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation. Additional side effects reported in the European Union include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low levels of thyroid hormones).

Dostarlimab was approved for the treatment of endometrial cancer in both the United States and the European Union in April 2021.

Based on the Garnet trial, dostarlimab gained accelerated approval from the US Food and Drug Administration (FDA) in April 2021, and full approval in February 2023.